SCHEMBL1384289

SCHEMBL1384289

Fc1ccc(-n2ncc(-c3cc4c(nn3)CCCCC4)c2C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
HTT P42858 3/20 0.46
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
P2RX7 Q99572 1/20 0.35
NR3C1 P04150 4/20 0.34
PGR P06401 2/20 0.34
PDK2 Q15119 2/20 0.34
TRPV1 Q8NER1 1/20 0.33
PDK1 Q15118 1/20 0.32
TP53 P04637 1/20 0.32
HTR2C P28335 1/20 0.32
NTRK1 P04629 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382475 1.00 LMNA (0.47) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1384543 0.90 LMNA (0.39) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1383415 0.90 POLB (0.45) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1382947 0.89 POLB (0.46) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1382991 0.79 KDM4E (0.42) SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL2322160 0.74 LMNA (0.45) LMNASMN1; SMN2HTTALDH1A1POLB
SCHEMBL1383468 0.73 AR (0.41) KMT2AHTR2C
SCHEMBL1386887 0.73 TRPA1 (0.38) KMT2AHTR2CNTRK1
SCHEMBL1386631 0.73 AR (0.41) KMT2AHTR2C
SCHEMBL1383974 0.73 TRPA1 (0.38) KMT2AHTR2CNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4787321-B2 2011-10-05 JP claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP claimed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP claimed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 LMNA 2625/4885SMN1; SMN2 2843/4885HTT 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.